Does the media prefer PTCT or ABCL?

In the previous week, PTC Therapeutics had 14 more articles in the media than AbCellera Biologics. MarketBeat recorded 18 mentions for PTC Therapeutics and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.14 beat PTC Therapeutics' score of 0.40 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or ABCL?

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 5 mentions for Mirum Pharmaceuticals and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.14 beat Mirum Pharmaceuticals' score of 0.98 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RYTM or ABCL?

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.14 beat Rhythm Pharmaceuticals' score of 0.71 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CNTA or ABCL?

In the previous week, Centessa Pharmaceuticals and Centessa Pharmaceuticals both had 4 articles in the media. AbCellera Biologics' average media sentiment score of 1.14 beat Centessa Pharmaceuticals' score of 0.73 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COGT or ABCL?

In the previous week, AbCellera Biologics had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for AbCellera Biologics and 3 mentions for Cogent Biosciences. AbCellera Biologics' average media sentiment score of 1.14 beat Cogent Biosciences' score of 0.74 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AbCellera Biologics (ABCL) Competitors

$7.38 +0.72 (+10.81%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$7.40 +0.02 (+0.28%)

As of 06/26/2026 07:59 PM Eastern

Compare

ABCL vs. PTCT, MIRM, RYTM, CNTA, and COGT

Should you buy AbCellera Biologics stock or one of its competitors? MarketBeat compares AbCellera Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AbCellera Biologics include PTC Therapeutics (PTCT), Mirum Pharmaceuticals (MIRM), Rhythm Pharmaceuticals (RYTM), Centessa Pharmaceuticals (CNTA), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does AbCellera Biologics compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and AbCellera Biologics (NASDAQ:ABCL) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

PTC Therapeutics has higher revenue and earnings than AbCellera Biologics. PTC Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	4.05	$682.64M	-$2.33	N/A
AbCellera Biologics	$75.13M	30.00	-$146.41M	-$0.48	N/A

In the previous week, PTC Therapeutics had 14 more articles in the media than AbCellera Biologics. MarketBeat recorded 18 mentions for PTC Therapeutics and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.14 beat PTC Therapeutics' score of 0.40 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has a net margin of -22.58% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

PTC Therapeutics currently has a consensus price target of $91.36, suggesting a potential upside of 8.20%. AbCellera Biologics has a consensus price target of $7.80, suggesting a potential upside of 5.69%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe PTC Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

61.4% of AbCellera Biologics shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

PTC Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Summary

PTC Therapeutics and AbCellera Biologics tied by winning 8 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and AbCellera Biologics (NASDAQ:ABCL) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Mirum Pharmaceuticals currently has a consensus target price of $139.80, suggesting a potential upside of 13.12%. AbCellera Biologics has a consensus target price of $7.80, suggesting a potential upside of 5.69%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Mirum Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 5 mentions for Mirum Pharmaceuticals and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.14 beat Mirum Pharmaceuticals' score of 0.98 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$569.61M	13.23	-$23.36M	-$13.61	N/A
AbCellera Biologics	$75.13M	30.00	-$146.41M	-$0.48	N/A

Mirum Pharmaceuticals has a net margin of -140.24% compared to AbCellera Biologics' net margin of -181.75%. Mirum Pharmaceuticals' return on equity of -11.28% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

61.4% of AbCellera Biologics shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Mirum Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Summary

Mirum Pharmaceuticals beats AbCellera Biologics on 10 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and AbCellera Biologics (NASDAQ:ABCL) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Rhythm Pharmaceuticals presently has a consensus target price of $133.13, suggesting a potential upside of 21.20%. AbCellera Biologics has a consensus target price of $7.80, suggesting a potential upside of 5.69%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Rhythm Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

AbCellera Biologics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	39.67	-$196.54M	-$3.13	N/A
AbCellera Biologics	$75.13M	30.00	-$146.41M	-$0.48	N/A

Rhythm Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.14 beat Rhythm Pharmaceuticals' score of 0.71 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.4% of AbCellera Biologics shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

Summary

Rhythm Pharmaceuticals and AbCellera Biologics tied by winning 8 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and AbCellera Biologics (NASDAQ:ABCL) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Centessa Pharmaceuticals currently has a consensus price target of $41.33, indicating a potential upside of 2.06%. AbCellera Biologics has a consensus price target of $7.80, indicating a potential upside of 5.69%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts clearly believe AbCellera Biologics is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

AbCellera Biologics has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
AbCellera Biologics	$75.13M	30.00	-$146.41M	-$0.48	N/A

In the previous week, Centessa Pharmaceuticals and Centessa Pharmaceuticals both had 4 articles in the media. AbCellera Biologics' average media sentiment score of 1.14 beat Centessa Pharmaceuticals' score of 0.73 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Centessa Pharmaceuticals has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Summary

AbCellera Biologics beats Centessa Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does AbCellera Biologics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and AbCellera Biologics (NASDAQ:ABCL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, AbCellera Biologics had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for AbCellera Biologics and 3 mentions for Cogent Biosciences. AbCellera Biologics' average media sentiment score of 1.14 beat Cogent Biosciences' score of 0.74 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Cogent Biosciences presently has a consensus target price of $43.73, indicating a potential upside of 14.72%. AbCellera Biologics has a consensus target price of $7.80, indicating a potential upside of 5.69%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Cogent Biosciences has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

AbCellera Biologics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
AbCellera Biologics	$75.13M	30.00	-$146.41M	-$0.48	N/A

61.4% of AbCellera Biologics shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

AbCellera Biologics beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.

Get AbCellera Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABCL vs. The Competition

Export

Metric	AbCellera Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.03B	$3.56B	$6.70B	$12.21B
Dividend Yield	N/A	2.25%	2.67%	6.13%
P/E Ratio	-15.37	21.75	25.90	24.18
Price / Sales	30.00	341.41	579.30	113.38
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	2.28	8.34	10.78	6.36
Net Income	-$146.41M	$23.91M	$3.58B	$337.99M
7 Day Performance	33.45%	3.42%	2.22%	0.10%
1 Month Performance	35.66%	1.55%	1.12%	-0.11%
1 Year Performance	104.43%	65.22%	34.29%	27.61%

AbCellera Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABCL AbCellera Biologics	1.7198 of 5 stars	$7.38 +10.8%	$7.80 +5.7%	+97.3%	$2.03B	$75.13M	N/A	500	Positive News Gap Down High Trading Volume
PTCT PTC Therapeutics	2.3332 of 5 stars	$75.14 +0.6%	$91.36 +21.6%	+70.4%	$6.23B	$1.73B	N/A	1,410	News Coverage Insider Trade
MIRM Mirum Pharmaceuticals	2.2605 of 5 stars	$99.35 -0.2%	$138.36 +39.3%	+144.4%	$6.06B	$521.31M	N/A	140	Analyst Downgrade
RYTM Rhythm Pharmaceuticals	2.5227 of 5 stars	$88.38 +0.8%	$131.81 +49.1%	+78.8%	$6.06B	$217.17M	N/A	140	Insider Trade
CNTA Centessa Pharmaceuticals	1.7124 of 5 stars	$39.72 -0.1%	$41.33 +4.1%	N/A	$5.93B	$15M	N/A	200	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABCL) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Competitors

ABCL vs. PTCT, MIRM, RYTM, CNTA, and COGT

How does AbCellera Biologics compare to PTC Therapeutics?

Summary

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Centessa Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Competitors

ABCL vs. PTCT, MIRM, RYTM, CNTA, and COGT

How does AbCellera Biologics compare to PTC Therapeutics?

Which has preferable valuation & earnings, PTCT or ABCL?

Does the media prefer PTCT or ABCL?

Is PTCT or ABCL more profitable?

Do analysts prefer PTCT or ABCL?

Do institutionals and insiders hold more shares of PTCT or ABCL?

Which has more volatility and risk, PTCT or ABCL?

Summary

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Do analysts recommend MIRM or ABCL?

Does the media prefer MIRM or ABCL?

Which has preferable earnings & valuation, MIRM or ABCL?

Is MIRM or ABCL more profitable?

Do institutionals & insiders have more ownership in MIRM or ABCL?

Which has more volatility and risk, MIRM or ABCL?

Summary

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

Do analysts rate RYTM or ABCL?

Which has preferable earnings and valuation, RYTM or ABCL?

Which has more risk and volatility, RYTM or ABCL?

Does the media refer more to RYTM or ABCL?

Do insiders & institutionals have more ownership in RYTM or ABCL?

Is RYTM or ABCL more profitable?

Summary

How does AbCellera Biologics compare to Centessa Pharmaceuticals?

Do analysts recommend CNTA or ABCL?

Which has higher earnings & valuation, CNTA or ABCL?

Does the media prefer CNTA or ABCL?

Do institutionals & insiders believe in CNTA or ABCL?

Is CNTA or ABCL more profitable?

Which has more risk and volatility, CNTA or ABCL?

Summary

How does AbCellera Biologics compare to Cogent Biosciences?

Does the media prefer COGT or ABCL?

Which has more risk and volatility, COGT or ABCL?

Do analysts rate COGT or ABCL?

Is COGT or ABCL more profitable?

Which has higher valuation and earnings, COGT or ABCL?

Do insiders & institutionals hold more shares of COGT or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools